British biotechs unveil new partnership deals
Tuesday 14 September 1999
Vanguard Medica, the pounds 80m migraine and psoriasis researcher, has secured an agreement with Menarini, a privately owned Italian company, to distribute its frovatriptan treatment for acute migraine in Europe. Meanwhile SkyePharma, which is capitalised at pounds 283m and modifies other company's drugs, has struck a deal with SmithKline Beecham to tweak its Requip treatment for Parkinson's disease.
Frovatriptan is expected to be launched in Europe by next June, with the US launch following shortly afterwards.
SkyePharma's tie-up with SmithKline sees it receiving milestone payments and royalties, along with an $8m investment in SkyePharma's equity. SkyePharma is to transform Requip from a three-times-a-day to a once- daily treatment.
Vanguard's shares closed up 7.5p at 242.5p. SkyePharma closed 2.5p ahead at 60p.
- 1 Howard Jacobson: Let's see the 'criticism' of Israel for what it really is
- 2 Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
- 4 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
There’s a nasty smell in the political air – and it’s coming from the Tories
Vanessa Feltz criticises 'vile' reaction to Rolf Harris allegations
iJobs Money & Business
£60000 - £75000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£60000 per annum: Harrington Starr: A leading provider in investment managemen...
£600 - £700 per day: Harrington Starr: AVS, JVS Openlink Endur Developer JVS, ...
£30000 per annum: Harrington Starr: A global leader in trading platforms and e...